Structure-function insights into elusive Mycobacterium tuberculosis protein Rv1916

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Tuberculosis (TB) poses a significant global health threat, driven by persistent Mycobacterium tuberculosis (Mtb) strains.
• Long TB treatment durations contribute to drug resistance, necessitating novel therapeutic targets.
• Isocitrate lyase (ICL) is vital for Mtb persistence and absent in humans, making it a promising drug target.

Purpose of the Study:

• To investigate the function and activity of Rv1916, a putative isocitrate lyase 2 (ICL2) component from Mtb.
• To explore the potential of Rv1916 as a novel drug target against persistent Mtb.
• To characterize the enzymatic activities of recombinant Rv1916.

Main Methods:

• Recombinant production of Rv1916 in a heterologous E. coli host.
• In vitro enzymatic assays to determine isocitrate lyase (ICL) and methylisocitrate lyase (MICL) activities.
• In silico analysis to predict protein function and identify unique domains.

Main Results:

• Recombinant Rv1916 was successfully produced in E. coli.
• Rv1916 demonstrated both ICL and MICL activities in vitro, similar to Mtb ICL1.
• In silico analysis suggested a role for the unique mycobacterial domain IV in secondary metabolite synthesis.

Conclusions:

• Rv1916 is enzymatically active and possesses dual ICL/MICL functions, supporting its role in Mtb.
• The findings highlight Rv1916 as a potential drug target for combating persistent and drug-resistant Mtb.
• Further research into Rv1916 and its unique domains could lead to new anti-TB strategies.